Cytotoxic chemotherapy for pancreatic neuroendocrine tumors
|
|
- Cuthbert Nelson
- 6 years ago
- Views:
Transcription
1 J Hepatobiliary Pancreat Sci (2015) 22: DOI: /jhbp.257 TOPIC Cytotoxic chemotherapy for pancreatic neuroendocrine tumors Takuji Okusaka Hideki Ueno Chigusa Morizane Shunsuke Kondo Yasunari Sakamoto Hideaki Takahashi Izumi Ohno Satoshi Shimizu Shuichi Mitsunaga Masafumi Ikeda Published online: 3 May Japanese Society of Hepato-Biliary-Pancreatic Surgery Abstract Advanced neuroendocrine tumors are incurable, and most will succumb to the disease. Chemotherapies with cytotoxic agents such as streptozocin, 5-fluorouracil, or temozolomide have been frequently used as drug therapies for neuroendocrine tumors. Streptozocin, which is the only approved cytotoxic agent available for the treatment of this disease in many countries, has been considered a key agent for the treatment of advanced neuroendocrine tumors based on the results of phase III studies. However, the widespread acceptance of streptozocin-based chemotherapy for this indication has been limited by concerns regarding toxicity. Recent prospective and retrospective studies showed the promising activity of a temozolomide-based regimen, although an adequate prospective controlled study defining the role of temozolomide in the treatment of neuroendocrine tumors is lacking. The promising activity of cytotoxic agents awaits confirmation; solid evidence-based recommendations and treatment decisions are needed for the optimal use of chemotherapy against this disease. Keywords Chemotherapy Fluoropyrimidine Neuroendocrine tumor Streptozocin Temozolomide therapy with alkylating agents, such as streptozocin and temozolomide. Chemotherapy primarily with platinumcontaining drugs, such as cisplatin and carboplatin, have been used for poorly differentiated type, i.e. neuroendocrine carcinoma (NEC), according to the protocols for small-cell lung cancer. Because of this considerable variation in treatment regimens according to the degree of differentiation, a precise pathological diagnosis is necessary before starting treatment. In this article, we review the results in prospective and retrospective studies of cytotoxic chemotherapy for NET G1/G2 and discuss the place of cytotoxic chemotherapy for this disease. Chemotherapies with alkylating agents, such as streptozocin, dacarbazine, and temozolomide, combined with the antimetabolites 5-FU and capecitabine and/or the anthracycline anticancer drugs doxorubicin and epirubicin have been assessed the most frequently and are in widespread use for the treatment of NET G1/G2. However, solid evidence of effectiveness obtained in a large-scale, phase 3 clinical trial has not been obtained for any of these regimens, and a global consensus on a standard treatment has not yet been established. Introduction The main cytotoxic chemotherapy regimens used to treat well-differentiated pancreatic neuroendocrine tumors (NETs) (i.e. NET G1/G2) have consisted primarily of anticancer drug T. Okusaka ( ) H. Ueno C. Morizane S. Kondo Y. Sakamoto Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo , Japan tokusaka@ncc.go.jp H. Takahashi I. Ohno S. Shimizu S. Mitsunaga M. Ikeda Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan Streptozocin (Table 1) [1 14] Streptozocin is a nitrosourea alkylating agent that is known to be taken up into cells by the glucose transport protein GLUT2 and to cause cell damage. Because GLUT2 is strongly expressed in pancreatic beta cells, streptozocin has been widely used to create animal models of diabetes mellitus. In 1980, Moertel et al. conducted a randomized study comparing streptozocin alone and streptozocin + 5-FU. Based on their results, which showed a response rate of 36% and a median survival time of 16.5 months in the streptozocin-alone group and a response rate of 63% and a median survival time of 26 months in the streptozocin + 5-FU group; they reported
2 J Hepatobiliary Pancreat Sci (2015) 22: Table 1 Outcomes for streptozocin-based chemotherapy (median, months) (median, months) Primary site Author Year Reference Streptozocin NA NA Pancreas only Broder LE Streptozocin NA 16.5 Pancreas only Moertel CG Streptozocin + 5-FU Streptozocin + Doxorubicin NA 10.9 Pancreas and Frame J Streptozocin + 5-FU / NA NA Pancreas only Eriksson B Doxorubicin Chlorozotocin Pancreas only Moertel C Streptozocin + 5-FU NA 16.8 Streptozocin + Doxorubicin Streptozocin + Doxorubicin NA >21 Pancreas only Rivera E FU Streptozocin + Doxorubicin 16 6 NA >10 Pancreas only Cheng PN Streptozocin + Doxorubicin Pancreas only McCollum AD Streptozocin + Doxorubicin Pancreas only Delaunoit T Streptozocin + Doxorubicin Pancreas only Kouvaraki MA FU Streptozocin + Doxorubicin NA 12 Pancreas and Pavel M Streptozocin + Liposomal Pancreas only Fjallskog ML Doxorubicin Streptozocin + Cisplatin Pancreas and Turner NC Streptozocin Pancreas and Meyer T Streptozocin + + Cisplatin that both a better response rate and a longer survival time were obtained using streptozocin + 5-FU [2]. In 1992, Moertel et al. conducted a 3-arm phase III comparative study comparing a chlorozotocin arm, a streptozocin + 5-FU arm, and a streptozocin + doxorubicin arm. Based on their results, which showed a response rate of 69% and median survival time of 26.4 months in the streptozocin + doxorubicin arm, they reported that significantly more favorable results were obtained in the streptozocin + doxorubicin arm, compared with the other two therapies [5]. Although both the response rate (69%) and the median survival time (26.4 months) obtained using streptozocin + doxorubicin in the phase III study were excellent, most subsequent studies have not confirmed these results [7 9]; consequently, the results of the previous phase III study are sometimes viewed with skepticism. Concerns over the adverse effects of this combination therapy, including gastrointestinal and renal toxicities, have also been pointed out. However, a streptozocin-containing regimen, streptozocin + 5-FU, has been shown to prolong the survival time of with gastrointestinal NETs in a phase III study [15], and streptozocin is considered to be a key drug in the treatment of pancreatic and gastrointestinal NETs. Dacarbazine (Table 2) [16 21] Dacarbazine is an alkylating agent that damages DNA through its diazomethane-mediated alkylating action, displaying an antitumor effect; the drug is used to treat malignant melanoma, Hodgkin lymphoma, sarcoma, and other cancers. Dacarbazine has also been used to treat pancreatic NETs for a relatively long time, and it has been assessed alone and in combination with 5-FU, epirubicin, leucovorin, and other agents. A phase II study of dacarbazine alone was conducted in 50 pancreatic NET, and relatively good results, with a response rate of 34% and a survival time of 19.3 months, were obtained [19]. Most studies for dacarbazinebased therapy have been conducted using a three-drug combination therapy with 5-FU and epirubicin, and such studies have reported response rates of 20% 40%, a progression-free survival () time of months, a median survival time of months, and major adverse reactions consisting of
3 630 J Hepatobiliary Pancreat Sci (2015) 22: Table 2 Outcomes for dacarbazine-based chemotherapy Primary site Author Year Reference Leucovorin NA NA Pancreas and Di Bartolomeo M NA NA Pancreas and Bajetta E NA NA Pancreas and Ollivier S Dacarbazine NA 19.3 Pancreas only Ramanathan RK Pancreas and Bajetta E Pancreas and Walter T Table 3 Outcomes for temozolomide-based chemotherapy Primary site Author Year Reference Thalidomide >26 >26 Pancreas and Temozolomide Pancreas and Kulke MH >24 Pancreas only Strosberg JR Pancreas and Ekeblad S Fine RL Pancreas only Saif MW >22 >29.1 Pancreas and NA Pancreas and 29 NA Pancreas and Fine R Abbasi S Peixoto RD myelosuppression, mucocutaneous disorders, and nausea and vomiting [16, 17, 20, 21]. Temozolomide (Table 3) [22 29] Temozolomide is an oral alkylating agent that is used to treat glioblastoma and melanoma. Because the side-effects of temozolomide are mild and it is an oral drug, temozolomide chemotherapy is expected to be less stressful for, and several studies of combination therapies with other drugs have been conducted in addition to a study of temozolomide alone. When used as a monotherapy, the response rate was 14%, the median was 7 months, and the median survival time was 16 months [23]. While the results of temozolomide monotherapy were marginal, all the studies that have been conducted examining combination therapy with capecitabine have reported promising results with regard to the response rate,, and survival time, and this combination, in particular, has attracted interest [24 29]. The Eastern Cooperative Oncology Group (ECOG) is currently conducting a
4 J Hepatobiliary Pancreat Sci (2015) 22: randomized phase II study examining temozolomide versus temozolomide + capecitabine (ClinicalTrials.gov Identifier: NCT ). The primary endpoint is, and the estimated enrollment is 145, with an estimated primary completion date of December Alkylating agents, including temozolomide, induce the methylation of the O 6 -position of guanine, which results in DNA mismatching and ultimately results in apoptosis and tumor cell death. O 6 -methylguanine DNA methyltransferase (MGMT) is known to specifically remove the methyl/alkyl group from the O 6 -position of guanine [30]. Kulke et al. reported that MGMT deficiency was associated with the temozolomide response in with NET, and they suggested that the MGMT status could be used as a predictive marker to identify NET who are likely to respond to treatment with alkylating agents, such as temozolomide [31]. Other drugs (Table 4) [32 37] In addition to the alkylating agents described above, other anticancer drugs, including 5-FU, paclitaxel, gemcitabine, and oxaliplatin, have been used in clinical studies examining pancreatic NETs, but all of these studies were conducted using small numbers of, and no randomized controlled studies have been performed. The platinum-containing drug oxaliplatin is often used in the gastrointestinal tract in combination with other drugs, mainly with fluoropyrimidines, (including 5-FU and capecitabine). Some reports have described the use of oxaliplatin in combination with capecitabine in pancreatic NETs, and response rates of about 30%, a median of 9.8 months, and a median survival time of more than 24 months have been reported [35, 37]. When undergo treatment with gemcitabine [34] or FOLFIRI [36], which have been used to treat pancreatic cancer or colorectal cancer, the response rates have been only about 0% 5%. Discussion Almost all the clinical studies on cytotoxic chemotherapy for NETs have been conducted in the form of single-arm studies on small numbers of without a control group. The study by Moertel et al. was the sole randomized controlled study to report that cytotoxic chemotherapy, consisting of streptozocin + doxorubicin combination therapy, prolonged the survival time [5]; however, because of the small number of and the fact that it was reported in 1992 and is a relatively old study, the reliability of the results is poor. Consequently, no cytotoxic chemotherapy regimen for which a global consensus has been achieved has been established as a standard therapy. Because molecularly targeted drugs, including everolimus and sunitinib, have recently been shown to be useful in large-scale randomized controlled studies and have been accepted as a standard therapy [38, 39], the place of cytotoxic chemotherapy in the treatment of NETs has become even more uncertain. However, numerous reports of cytotoxic chemotherapy regimens have yielded promising results, and these findings are expected to play a certain role in the treatment of NETs. Pancreatic NETs progress relatively slowly. The general condition of is relatively good, even in unresectable cases, and long survival times are common. At present, no standard treatments have been established as a second-line therapy after molecularly targeted therapy, and cytotoxic chemotherapy is also expected to become positioned as a standard chemotherapy based on the results of high-quality randomized controlled studies examining who cannot Table 4 Outcomes for other regimens Primary site Author Year Reference Chlorozotocin NA 25 Pancreas only Paclitaxel Pancreas and Gemcitabine Pancreas and + Oxaliplatin Irinotecan +Leucovorin + Oxaliplatin NA >24 Pancreas and NA Pancreas only NA Pancreas and Bukowski RM Ansell SM Kulke MN Bajetta E Brixi-Benmansour H Ferrarotto R
5 632 tolerate everolimus or sunitinib or have failed to respond to these drugs. In addition, the usefulness of both everolimus and sunitinib has been demonstrated in placebo-controlled phase III trials, but which of the two, molecularly targeted therapy or cytotoxic chemotherapy, is superior has not yet been ascertained. The response rates to molecularly targeted drugs are relatively low (sunitinib, 9.3% [39]; everolimus, 5% [38]), and a cytoreductive effect cannot be expected. However, several cytotoxic chemotherapy regimens that yield high response rates have been reported. Thus, cytotoxic chemotherapy could be considered as a first-line treatment for who manifest symptoms because of their tumor burden or for in whom cytoreduction appears to provide a clinical advantage, such as with locally advanced cases for which surgery is possible [40 42]. Although predictors associated with a response to chemotherapy have not been fully elucidated, some markers may have the potential to allow the selection of who may benefit from chemotherapy. Turner et al. reported that both the mitotic index and Ki67 were associated with a response to chemotherapy consisting of 5-fluorouracil, cisplatin, and streptozocin [13]. For the mitotic index, the response rate increased from 15% for tumors with a mitotic index of 0 1 to 55% for tumors with a mitotic index 5 (P=0.008); for Ki67, the response rate increased from 18% for a Ki67 value of <10% to 52% for a Ki67 value of >24% (P=0.019). Kulke et al. reported that MGMT deficiency was associated with a response to temozolomide. At present, the evidence for cytotoxic chemotherapy as a standard therapy is inadequate, but there is a strong possibility that its usefulness will be demonstrated, and proper evaluation using high-quality clinical studies is needed. Clarifying which should be treated and the optimal timing of the treatment are additional tasks that should be addressed in the future. Because pancreatic NET is a rare disease, a multicenter study will be needed, and a global-level initiative with the aim of establishing an optimal treatment algorithm is earnestly desired. Conflict of interest Research funding: Takuji Okusaka, Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd. References 1. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52. Ann Intern Med. 1973;79: Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced isletcell carcinoma. N Engl J Med. 1980;303: J Hepatobiliary Pancreat Sci (2015) 22: Frame J, Kelsen D, Kemeny N, Cheng E, Niedzwiecki D, Heelan R, et al. A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am J Clin Oncol. 1988;11: Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 with endocrine pancreatic tumors. Cancer. 1990;65: Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326: Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for with metastatic islet-cell carcinoma. Am J Clin Oncol. 1998;21: Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of with advanced islet cell carcinoma. Cancer. 1999;86: McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, et al. Lack of efficacy of streptozocin and doxorubicin in with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004;27: Delaunoit T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer. 2004;40: Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22: Pavel ME, Baum U, Hahn EG, Hensen J. Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. Int J Gastrointest Cancer. 2005;35: Fjallskog ML, Janson ET, Falkmer UG, Vatn MH, Oberg KE, Eriksson BK. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology. 2008;88: Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer. 2010;102: Meyer T, Qian W, Caplin ME, Armstrong G, Lao-Sirieix SH, Hardy R, et al. and streptozocin +/- cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. Eur J Cancer. 2014;50: Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG, Eastern Cooperative Oncology G. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23: Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, et al. A phase II trial of dacarbazine, fluorouracil and epirubicin in with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol. 1995;6: Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of with neuroendocrine tumors. Cancer. 1998;83: Ollivier S, Fonck M, Becouarn Y, Brunet R. Dacarbazine, fluorouracil, and leucovorin in with advanced neuroendocrine tumors: a phase II trial. Am J Clin Oncol. 1998;21: Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group- E6282. Ann Oncol. 2001;12:
6 J Hepatobiliary Pancreat Sci (2015) 22: Bajetta E, Del Vecchio M, Vitali M, Martinetti A, Ferrari L, Queirolo P, et al. A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma. Tumori. 2001;87: Walter T, Bruneton D, Cassier PA, Hervieu V, Pilleul F, Scoazec JY, et al. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in with advanced well-differentiated neuroendocrine tumors. Clin Colorectal Cancer. 2010;9: Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24: Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13: Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117: Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, et al. and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71: Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G, Rodriguez T. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pnets) after failing previous therapy. JOP. 2013;14: Fine RL, Gulati AP, Tsushima DA, Mowatt KB, Oprescu A, Bruce JN, et al. Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and welldifferentiated metastatic neuroendocrine tumors. J Clin Oncol. 2014;32: Abbasi S, Kashashna A, Albaba H. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience. Pancreas. 2014;43: Peixoto RD, Noonan KL, Pavlovich P, Kennecke HF, Lim HJ. Outcomes of treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non- PNETs. J Gastrointest Oncol. 2014;5: Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006;12: Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in with neuroendocrine tumors. Clin Cancer Res. 2009;15: Bukowski RM, Tangen C, Lee R, Macdonald JS, Einstein AB, Jr., Peterson R, et al. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1992;10: Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J. A Phase II study of high-dose paclitaxel in with advanced neuroendocrine tumors. Cancer. 2001;91: Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004;101: Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007;59: Brixi-Benmansour H, Jouve JL, Mitry E, Bonnetain F, Landi B, Hentic O, et al. Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. Dig Liver Dis. 2011;43: Ferrarotto R, Testa L, Riechelmann RP, Sahade M, Siqueira LT, Costa FP, et al. Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors. Rare Tumors. 2013;5:e Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364: Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard- Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364: Weatherstone K, Meyer T. Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Target Oncol. 2012;7: Hammel P, Hentic O, Neuzillet C, Faivre S, Raymond E, Ruszniewski P. New treatment options with cytotoxic agents in neuroendocrine tumours. Target Oncol. 2012;7: Yao JC, Phan AT. Optimising therapeutic options for with advanced pancreatic neuroendocrine tumours. Eur Oncol Haematol. 2012;8:
NICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Neuro-endocrine Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationUpdates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010
HIGHLIGHT ARTICLE Updates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010 Susan Alsamarai 1, Steven K Libutti 2, Muhammad Wasif Saif
More informationStreptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan
J Gastroenterol (2015) 50:769 775 DOI 10.1007/s00535-014-1006-3 ORIGINAL ARTICLE LIVER, PANCREAS, AND BILIARY TRACT Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine
More informationLow dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors
Mueller et al. BMC Cancer (206) 6:645 DOI 0.86/s2885-06-2642- RESEARCH ARTICLE Open Access Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors Daniela
More informationNeuroendocrine Tumors: Treatment Updates Highlights from the 2013 ASCO Annual Meeting. Chicago, IL, USA; May 30 - June 4, 2013
HIGHLIGHT ARTICLE Neuroendocrine Tumors: Treatment Updates Highlights from the 2013 ASCO Annual Meeting. Chicago, IL, USA; May 30 - June 4, 2013 Simon Khagi, Muhammad Wasif Saif Tufts Medical Center, Tufts
More informationTRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS
TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND
More informationSystemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update
Focused Review 777 Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update Diane L. Reidy-Lagunes, MD, MS Abstract Well-differentiated neuroendocrine tumors (NETs) can be subdivided into
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1. Therapies for non-men1 pancreatic neuroendocrine tumours (NETs) (published after 2011) Somatostatin analogues Tumour type a Intervention Number of participants/information available
More informationChemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
British Journal of Cancer (2010) 102, 1106 1112 All rights reserved 0007 0920/10 $32.00 www.bjcancer.com Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours NC Turner
More informationPancreatic NeuroEndocrine Tumors. Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium
Pancreatic NeuroEndocrine Tumors Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Epidemiology Overall incidence 1.8 to 2.6 SEER, Europe Peak in 5 th and 6 th decade Incidence
More informationOUTLINE. Background. What in NEC. What in NET G3. What in Minen/Manec. Future prospective. Conclusions
OUTLINE 1 2 3 4 5 6 Background What in NEC What in NET G3 What in Minen/Manec Future prospective Conclusions Median OS of poorly differentiated neuroendocrine carcinomas (NECs) The median survival for
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL NEUROENDOCRINE GASTRO-ENTERO-PANCREATIC TUMOURS GI Site Group Neuroendocrine gastro-entero-pancreatic tumours Authors: Dr.
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationPancreatic Neuroendocrine Tumors: Entering a New Era Highlights from the 2012 ASCO Gastrointestinal Cancers Symposium.
HIGHLIGHT ARTICLE Pancreatic Neuroendocrine Tumors: Entering a New Era Highlights from the 2012 ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, USA. January 19-21, 2012 Paul E Oberstein 1,
More informationCisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas
Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas Satoru Iwasa 1, Chigusa Morizane 1*, Takuji Okusaka 1, Hideki
More informationDigestive and Liver Disease
Digestive and Liver Disease 44 (2012) 95 105 Contents lists available at SciVerse ScienceDirect Digestive and Liver Disease journal homepage: www.elsevier.com/locate/dld Review Article New treatment strategies
More informationRecent developments of oncology in neuroendocrine tumors (NETs)
Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in
More informationEverolimus for Advanced Pancreatic Neuroendocrine Tumors
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article for Advanced Pancreatic Neuroendocrine Tumors James C. Yao, M.D., Manisha H. Shah, M.D., Tetsuhide Ito, M.D., Ph.D., Catherine Lombard
More informationReference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer
More informationDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
Title page Pancreatic neuroendocrine tumors: a single-center 20-year experience with 100 patients A short title: One hundred patients with pancreatic NEN at a single center Contributing Authors: Satoshi
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationΧΗΜΕΙΟΘΕΡΑΠΕΙΑ ΣΤΑ ΝΕΤ: ΝΕΩΤΕΡΕΣ ΕΞΕΛΙΞΕΙΣ ΚΑΙ ΠΡΟΒΛΗΜΑΤΙΣΜΟΙ
ΧΗΜΕΙΟΘΕΡΑΠΕΙΑ ΣΤΑ ΝΕΤ: ΝΕΩΤΕΡΕΣ ΕΞΕΛΙΞΕΙΣ ΚΑΙ ΠΡΟΒΛΗΜΑΤΙΣΜΟΙ ΑΝΝΑ ΚΟΥΜΑΡΙΑΝΟΥ Ph.D ΔΙΕΥΘΥΝΤΡΙΑ ΕΣΥ, ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ ΑΙΜΑΤΟΛΟΓΙΚΗ-ΟΓΚΟΛΟΓΙΚΗ ΜΟΝΑΔΑ Δ ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΠΑΘΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ
More informationToward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives
Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts
More informationMaterials and Methods
Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas Rodrigo Ramella Munhoz, 1 Juliana Florinda de Mendonça Rego, 2 Anezka Rubim de Celis Ferrari, 2 Maria
More informationVision of the Future: Capecitabine
Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More information2015: Year in Review Results of Recent Trials
2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research
More informationNET del pancreas ben differenziato: la terapia oncologica. Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia
NET del pancreas ben differenziato: la terapia oncologica Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia Systemic treatment op:ons Somatosta:n analogues Interpheron
More informationPrognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas.
Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas. Halfdan Sorbye Medical Oncologist Professor, MD Dept of Oncology Haukeland Univ Hospital Bergen, Norway Gastroenteropancreatic
More informationPeptide receptor radionuclide therapy (PRRT) is a highly efficient
Journal of Nuclear Medicine, published on January 16, 2014 as doi:10.2967/jnumed.113.125336 Predictors of Long-Term Outcome in Patients with Well- Differentiated Gastroenteropancreatic Neuroendocrine Tumors
More informationGuideline A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Therapy of Incurable Gastroenteropancreatic Neuroendocrine Tumours S. Singh, D. Sivajohanathan, T.
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationA Phase II Trial of Uracil Tegafur (UFT) in Patients with Advanced Biliary Tract Carcinoma
Original Article Japanese Journal of Clinical Oncology Advance Access published July 15, 2005 Jpn J Clin Oncol doi:10.1093/jjco/hyi131 A Phase II Trial of Uracil Tegafur (UFT) in Patients with Advanced
More informationUnited States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment
Online Submissions: http://www.wjgnet.com/esps/ wjg@wjgnet.com doi:10.3748/wjg.v19.i15.2348 World J Gastroenterol 2013 April 21; 19(15): 2348-2354 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2013 Baishideng.
More informationSystemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid
Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University
More informationTwenty-six Cases of Advanced Ampullary Adenocarcinoma Treated with Systemic Chemotherapy
Jpn J Clin Oncol 2014;44(4)324 330 doi:10.1093/jjco/hyt237 Advance Access Publication 30 January 2014 Twenty-six Cases of Advanced Ampullary Adenocarcinoma Treated with Systemic Chemotherapy Hirokazu Shoji
More informationEfficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours
Original article Annals of Oncology 13: 614 621, 2002 DOI: 10.1093/annonc/mdf064 Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours E. Bajetta 1 *, L. Ferrari
More information9. Pharmacological therapy of neuroendocrine tumors
Tumori, 96: 847-857, 2010 9. Pharmacological therapy of neuroendocrine tumors Anja Rinke, Sergio Ricci, Emilio Bajetta, and Svetislav Jelic Evolving perspectives on antiproliferative effects of octreotide
More informationOriginal Article Clinical features of patients with pancreatic neuroendocrine neoplasms: a retrospective analysis of 61 cases in a cancer center
Int J Clin Exp Med 2017;10(3):4897-4904 www.ijcem.com /ISSN:1940-5901/IJCEM0045112 Original Article Clinical features of patients with pancreatic neuroendocrine neoplasms: a retrospective analysis of 61
More informationSystemic therapy for neuroendocrine tumours of gastroenteropancreatic origin
Page 1 of 37 Accepted Preprint first posted on 11 December 2009 as Manuscript ERC-09-0108 Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin Bristi Basu, Bhawna Sirohi & Pippa
More informationsunitinib 12.5mg, 25mg, 37.5mg, 50mg hard capsules (Sutent ) SMC No. (698/11) Pfizer Limited
sunitinib 12.5mg, 25mg, 37.5mg, 50mg hard capsules (Sutent ) SMC No. (698/11) Pfizer Limited 08 April 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationSecond-line systemic treatment for advanced cholangiocarcinoma
Original Article Second-line systemic treatment for advanced cholangiocarcinoma Jane E. Rogers 1, Lindsey Law 2, Van D. Nguyen 1, Wei Qiao 3, Milind M. Javle 2, Ahmed Kaseb 2, Rachna T. Shroff 2 1 Pharmacy
More informationReview of Gastrointestinal Carcinoid Tumors: Latest Therapies
Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationEvaluation of efficacy and toxicity of systemic chemotherapy of combined epirubicin, cisplatin and bolus 5- fluorouracil for hepatobiliary tumors
Turkish Journal of Cancer Volume 36, No.2, 2006 69 Evaluation of efficacy and toxicity of systemic chemotherapy of combined epirubicin, cisplatin and bolus 5- fluorouracil for hepatobiliary tumors GÜZ
More informationThe efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting*
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-1295-2 April 2014, Vol. 13, No. 4, P169 P173 The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different
More informationAn Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pnets)
Rare Cancers Ther (2015) 3:13 33 DOI 10.1007/s40487-015-0007-6 REVIEW An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pnets) Teresa Alonso-Gordoa. Juan José Díez. Javier Molina.
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationFactors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer
Curr Oncol, Vol. 21, pp. 181-186 doi: http://dx.doi.org/10.3747/co.21.1963 DELAYED TIME TO ADJUVANT CHEMOTHERAPY ORIGINAL ARTICLE Factors associated with delayed time to adjuvant chemotherapy in stage
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationBevacizumab in Advanced Adenocarcinoma of the Pancreas. Original Policy Date
5.01.13 Bevacizumab in Advanced Adenocarcinoma of the Pancreas Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationLong-Term Management of a Patient with Well-Differentiated Pulmonary Neuroendocrine Carcinoma: A Case Report
Published online: April 6, 2013 1662 6575/13/0061 0209$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationTGFβR1 Kinase Inhibitor
TGFβR1 Kinase Inhibitor Galunisertib, LY2157299 H 2 0 Prud homme GJ 1 ; Flavell RA, et al 2 Drug Discovery Platform: Cancer Angiogenesis and Tumor Microenvironment/Immuno-Oncology A Phase 1b/2 Dose-Escalation
More informationOverview. Author Summary: Abstract and Brief Discussion
Overview First Published Online October 1, 2014 DOI: 10.1634/theoncologist.2014-0223 Title: S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationPancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case
Case Report Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case Yang Wang, Dongbing Zhao Department of Abdominal Surgery, Cancer Institute & Hospital,
More informationPancreatic Neuroendocrine Tumors Therapy
REVIEW ARTICLE PANCREATIC NEUROENDOCRINE TUMORS Pancreatic Neuroendocrine Tumors Therapy Tara E Seery 1, Aditi Choudhry 2, Ann Eapen 2, Yu Cheng 2 1 Chan Soon-Shiong Institute for Medicine, United States
More informationNuevas alternativas en el manejo de TNE avanzados
Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationName of Policy: Panitumumab, Vectibix
Name of Policy: Panitumumab, Vectibix Policy #: 369 Latest Review Date: June 2014 Category: Pharmacology Policy Grade: B Background/Definitions: As a general rule, benefits are payable under Blue Cross
More informationMy name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.
Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.
More informationGastrinoma: Medical Management. Haley Gallup
Gastrinoma: Medical Management Haley Gallup Also known as When to put your knife down Gastrinoma Definition and History Diagnosis Historic Management Sporadic vs MEN-1 Defining surgical candidates Nonsurgical
More informationChemotherapy-induced HBV reactivation in cancer patients
Chemotherapy-induced HBV reactivation in cancer patients On behalf of Taiwan Cooperative Oncology Group (TCOG) HBV reactivation in lymphoma patients: What we have known HBV reactivation and hepatitis flares
More informationMetastatic Insulinoma: Current Molecular and Cytotoxic Therapeutic Approaches for Metastatic Well-Differentiated pannets
Molecular Insights in Patient Care 139 Metastatic Insulinoma: Current Molecular and Cytotoxic Therapeutic Approaches for Metastatic Well-Differentiated pannets Iulia Giuroiu, MD, a and Diane Reidy-Lagunes,
More informationChromogranin A as a predictor of radiological disease progression in neuroendocrine tumours
Original Article Page 1 of 7 Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours Roberta Elisa Rossi 1,2, Jorge Garcia-Hernandez 1, Tim Meyer 3, Christina Thirlwell
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationCan oncologists predict survival for patients with progressive disease after standard chemotherapies?
Curr Oncol, Vol. 21, pp. 84-90; doi: http://dx.doi.org/10.3747/co.21.1743 CLINICAL PREDICTION OF SURVIVAL BY ONCOLOGISTS ORIGINAL ARTICLE Can oncologists predict survival for patients with progressive
More informationSystemic Cytotoxic Therapy in advanced HCC
Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy
More informationReference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationOverview. Author Summary: Abstract and Brief Discussion
Overview First Published Online October 3, 2014 DOI: 10.1634/theoncologist.2014-0159 Title: A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic
More informationWorking Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Everolimus (Afinitor ) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin DSD: Horizon Scanning in Oncology Nr. 024 ISSN online 2076-5940
More informationOPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS
OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust
More informationPancreatic Neuroendocrine Tumours
UCLH Cancer Collaborative Pancreas Update Meeting 12 th July 2017 Pancreatic Neuroendocrine Tumours Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior
More informationCHAPTER 32. Advanced Metastatic Disease. Randomized Trials Versus Best Supportive Care. Chemotherapy Trials
21786_Ch32.qxd_447-460 1/20/05 9:09 AM Page 447 CHAPTER 32 Advanced Metastatic Disease Marcel Rozencweig, MD Daniel D. Von Hoff, MD Adenocarcinoma of the pancreas is an aggressive and rapidly fatal disease
More informationTeresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal
Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6
More informationWhere Are Anti-Angiogenic Agents Positioned Within Cancer Care Guidelines?
Introduction Additionally, other anti-angiogenic drugs, including sorafenib, sunitinib, axitinib, pazopanib, vandetanib, The development and subsequent use of drugs for treating cancer cabozantinib, and
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationHorizon Scanning Technology Summary. Temozolomide (Temodal) for advanced metastatic melanoma. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Temozolomide (Temodal) for advanced metastatic melanoma April 2007 This technology summary is based on information available at the
More informationTreatment of Liver Metastases in Patients with Neuroendocrine Tumors
International Journal of Hepatology Treatment of Liver Metastases in Patients with Neuroendocrine Tumors Guest Editors: Dan Granberg, Wouter de Herder, Dermot O Toole, and Larry Kvols Treatment of Liver
More informationClinical Trials for Liver and Pancreatic Cancer in Taiwan
Japan - Taiwan Joint Symposium on Medical Oncology Session 6 Hepatobiliary and pancreatic cancers Clinical Trials for Liver and Pancreatic Cancer in Taiwan Li-Tzong Chen 1,2 *, Jacqueline Whang-Peng 1,3
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationONCOLOGY LETTERS 2: , 2011
ONCOLOGY LETTERS 2: 241-245, 2011 Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following
More informationCancer Registry Report. Cancer Focus: Melanoma
Cancer Registry Report Cancer Focus: Melanoma In 2005, nearly 60,000 patients were diagnosed with melanoma, resulting in about 7800 deaths Fortunately, melanoma is often diagnosed in an early stage when
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationNET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες
NETMASTERCLASS 2017: an interactive workshop NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες Νικόλαος Τσουκαλάς MD, MSc, PhD Ογκολόγος - Παθολόγος, MSc Βιοπληροφορική Επιμελητής Α, Ογκολογικό Τμήμα Νοσηλευτικό
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationTGFβR1 Kinase Inhibitor
TGFβR1 Kinase Inhibitor Galunisertib, LY2157299 H 2 0 Derived from Prud homme GJ 1 ; Flavell RA, et al. 2 Drug Discovery Platform: Cancer Angiogenesis and Tumor Microenvironment/Immuno-Oncology A Phase
More informationCHEMOTHERAPY FOR METASTATIC GASTRIC CANCER
CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain
More informationEffectiveness of Chemotherapy for Advanced Adenocarcinoma of the Pancreas in Combined Modality Therapy
ORIGINAL ARTICLE Effectiveness of Chemotherapy for Advanced Adenocarcinoma of the Pancreas in Combined Modality Therapy Hiroyuki Kato, Hideyuki Wakasugi, Masaki Yokota, Masayuki Furukawa, Toshio Mukuta,
More informationIntegrating Oxaliplatin into the Management of Colorectal Cancer
Integrating Oxaliplatin into the Management of Colorectal Cancer HANS-JOACHIM SCHMOLL, a JIM CASSIDY b a Martin-Luther-University Halle-Wittenberg, Halle, Germany; b University of Aberdeen, Aberdeen, UK
More informationSUPPLEMENTARY INFORMATION In format provided by Sebti et al. (NOVEMBER 2011)
Supplementary Information S4 Clinical trials with farnesyltransferase inhibitors Drug(s) Disease Phase Patients Median Age Tipifarnib CR Clinical response PR HI SD PD MD FT or Prenylation Response rate
More informationQOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Abstract C-33 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday
More information